Monitoring Pregnancies Exposed to Galcanezumab for Migraine in a United States Administrative Claims Database
The accrual of a sufficient number of galcanezumab-exposed pregnancies represents a substantial, but not uncommon, barrier to conducting comparative analyses in pregnancy studies. Potential solutions that would allow for timely dissemination of important safety information to patients and providers may be available.
Authors
- Sarah R. Hoffman (ORCID: https://orcid.org/0000-0001-5629-160X)
- Stephan Lanes (ORCID: https://orcid.org/0000-0001-9536-6643)
- Krista Schroeder (ORCID: https://orcid.org/0000-0002-0589-2613)
- Francis Mawanda
- Dustin Ruff
- Christopher L. Crowe
Institutions
- Eli Lilly (United States) (US)
- Wilmington University (US)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/pds.70015
- Citations
- 1
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- Eli Lilly and Company